FRX vs. SLS, CRON, TEV, ABT, NOT, PYR, NVO, DNA, TLRY, and VBV
Should you be buying Fennec Pharmaceuticals stock or one of its competitors? The main competitors of Fennec Pharmaceuticals include Solaris Resources (SLS), Cronos Group (CRON), Tervita (TEV), Absolute Software Co. (ABT.TO) (ABT), Noront Resources (NOT), PyroGenesis Canada Inc. (PYR.V) (PYR), Novo Resources Corp. (NVO.V) (NVO), Dalradian Resources (DNA), Tilray Brands (TLRY), and VBI Vaccines (VBV). These companies are all part of the "pharmaceutical products" industry.
Fennec Pharmaceuticals vs. Its Competitors
Fennec Pharmaceuticals (TSE:FRX) and Solaris Resources (TSE:SLS) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.
In the previous week, Fennec Pharmaceuticals had 3 more articles in the media than Solaris Resources. MarketBeat recorded 5 mentions for Fennec Pharmaceuticals and 2 mentions for Solaris Resources. Solaris Resources' average media sentiment score of 0.30 beat Fennec Pharmaceuticals' score of 0.04 indicating that Solaris Resources is being referred to more favorably in the news media.
Solaris Resources has a consensus price target of C$14.25, indicating a potential upside of 90.51%. Given Solaris Resources' higher possible upside, analysts clearly believe Solaris Resources is more favorable than Fennec Pharmaceuticals.
Solaris Resources has a net margin of 0.00% compared to Fennec Pharmaceuticals' net margin of -2.30%. Fennec Pharmaceuticals' return on equity of 29.94% beat Solaris Resources' return on equity.
Fennec Pharmaceuticals has a beta of 0.25, indicating that its share price is 75% less volatile than the S&P 500. Comparatively, Solaris Resources has a beta of 1.9, indicating that its share price is 90% more volatile than the S&P 500.
Fennec Pharmaceuticals has higher revenue and earnings than Solaris Resources. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Solaris Resources, indicating that it is currently the more affordable of the two stocks.
52.8% of Fennec Pharmaceuticals shares are owned by institutional investors. Comparatively, 25.1% of Solaris Resources shares are owned by institutional investors. 16.2% of Fennec Pharmaceuticals shares are owned by insiders. Comparatively, 40.6% of Solaris Resources shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Fennec Pharmaceuticals beats Solaris Resources on 9 of the 16 factors compared between the two stocks.
Get Fennec Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for FRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding FRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fennec Pharmaceuticals Competitors List
Related Companies and Tools
This page (TSE:FRX) was last updated on 7/12/2025 by MarketBeat.com Staff
